Demand for Immunoassay CDMO in USA

Demand for Immunoassay CDMO in USA Market Size, Market Forecast and Outlook By FMI

The Immunoassay CDMO in USA market was valued at USD 4.20 billion in 2025, projected to reach USD 4.56 billion in 2026, and is forecast to expand to USD 10.30 billion by 2036 at a 8.5% CAGR. As per FMI, USA diagnostic and pharmaceutical companies are accelerating outsourcing of immunoassay manufacturing to specialised CDMOs to manage escalating FDA compliance costs and capacity constraints.

Summary of Demand for Immunoassay CDMO in USA Market

• Market Overview
  • The Immunoassay CDMO in USA market is valued at USD 4.20 billion in 2025 and is projected to reach USD 10.30 billion by 2036.
  • The industry is expected to grow at a 8.5% CAGR from 2026 to 2036, creating an incremental opportunity of USD 5.74 billion.
  • The market is a quality-compliance-driven outsourcing category where FDA cGMP enforcement, companion diagnostic pipeline expansion, and capacity constraints at integrated manufacturers define competitive positioning among USA CDMOs.
• Demand and Growth Drivers
  • Demand is rising as USA diagnostic and pharmaceutical companies outsource immunoassay manufacturing to manage escalating FDA compliance costs and internal capacity limitations.
  • Companion diagnostic pipeline expansion and point-of-care assay proliferation are generating sustained multi-year CDMO procurement cycles.
  • Smaller biotech firms without internal manufacturing capacity rely on CDMO partnerships to meet FDA filing timelines without capital expenditure.
  • West USA leads at 9.7% CAGR, followed by South USA at 8.7%, Northeast USA at 7.8%, and Midwest USA at 6.8%.
• Product and Segment View
  • The market includes services, end user, company size as primary segmentation dimensions.
  • Manufacturing and Production leads by Services with 53% share in 2026.
  • Diagnostic Companies leads by End User with 48.2% share in 2026.
• Geography and Competitive Outlook
  • West USA is the fastest-growing region at 9.7% CAGR, while South USA anchors the second-largest demand base.
  • Competition is shaped by technical specialisation, regulatory compliance capability, and integration depth, with key players including Firalis Molecular Precision, ProBio, Sanner GmbH, Biopharma Group, GTP Bioways.
• Analyst Opinion at FMI
  • Sabyasachi Ghosh, Principal Consultant, opines: 'FMI's analysis reveals that the immunoassay cdmo in usa market is entering a phase where procurement decisions are increasingly dictated by regulatory compliance timelines and measurable performance thresholds. Organisations that delay platform investment risk permanent lockout from competitive procurement tiers their counterparts are actively securing.'
• Strategic Implications / Executive Takeaways
  • Solution providers must secure certified integration pathways with tier-1 enterprise systems to qualify for forthcoming institutional procurement contracts.
  • Capital project directors should phase out legacy approaches and mandate native platform compatibility in all new equipment and software procurement specifications.
  • Technical teams must develop specialised competencies in services validation to demonstrate compliance parameters during the evaluation phase.

Demand for Immunoassay CDMO in USA Market Key Takeaways

Metric	Details
Industry Size (2026)	USD 4.56 billion
Industry Value (2036)	USD 10.30 billion
CAGR (2026 to 2036)	8.5%

Source: Future Market Insights, 2026

FMI is of the opinion that the convergence of rising companion diagnostic demand, tightening cGMP enforcement by FDA inspection programmes, and the clinical pipeline expansion of point-of-care immunoassay platforms is creating sustained multi-year procurement cycles for contract manufacturing services across the United States.

FMI analysts observe that regional demand distribution across the United States reflects the concentration of biopharmaceutical and diagnostics manufacturing clusters. West USA leads at 9.7% CAGR, supported by California and Pacific Northwest biotech hubs generating high-volume outsourcing contracts for lateral flow and chemiluminescence assay production. South USA follows at 8.7%, driven by Research Triangle and Texas-based diagnostic companies expanding contract manufacturing partnerships. Northeast USA registers 7.8% growth, anchored by the density of pharmaceutical headquarters in New Jersey and Connecticut channelling immunoassay development contracts. Midwest USA maintains 6.8% growth as medical device companies in Minnesota and Indiana diversify into companion diagnostic outsourcing. Based on FMI's report, states with active biotech tax incentive programmes show materially higher CDMO capacity utilisation rates compared to the national average.

Demand for Immunoassay CDMO in USA Market Definition

Based on FMI's report, the Immunoassay CDMO in USA market covers contract development and manufacturing services for immunoassay-based diagnostic products, including ELISA kits, lateral flow assays, chemiluminescence immunoassays, and related reagent systems outsourced by diagnostic, biotech, and pharmaceutical companies operating within the United States.

Demand for Immunoassay CDMO in USA Market Inclusions

Future Market Insights analysis covers contract manufacturing and production services, assay development and optimization, formulation and stability testing, and analytical services for immunoassay products. The scope encompasses regional market sizes across USA census regions, forecast projections from 2026 to 2036, and segmentation by service type, end user, and company size.

Demand for Immunoassay CDMO in USA Market Exclusions

The scope excludes in-house manufacturing by integrated diagnostic companies, contract services for non-immunoassay diagnostic platforms such as molecular diagnostics or clinical chemistry, and raw material supply without value-added development services.

Demand for Immunoassay CDMO in USA Market Research Methodology

• Primary Research: Analysts engaged with CDMO business development directors, diagnostic company outsourcing managers, and FDA regulatory affairs consultants to map procurement decision criteria and quality compliance timelines.
• Desk Research: Data collection aggregated FDA manufacturing inspection records, CMS reimbursement coding updates for diagnostic assays, and published CDMO capacity expansion disclosures from listed contract manufacturers.
• Market-Sizing and Forecasting: Baseline values derive from a bottom-up aggregation of immunoassay CDMO contract revenues within the United States, applying end-user outsourcing penetration curves and regulatory compliance cost escalation assumptions.
• Data Validation and Update Cycle: Projections are cross-validated against publicly reported contract manufacturing revenue guidance from major listed CDMOs and quarterly outsourcing expenditure trends disclosed by USA diagnostic companies.

Why is the Demand for Immunoassay CDMO in USA Growing?

The demand for immunoassay CDMO (Contract Development and Manufacturing Organization) services in the USA is growing due to the increasing demand for diagnostic tools, especially in immunoassay testing, which is vital for detecting and quantifying biomarkers in healthcare applications. Immunoassays are widely used in clinical diagnostics, drug discovery, and environmental testing, which has driven a greater need for reliable, scalable manufacturing solutions. As the global focus on healthcare and diagnostics intensifies, the demand for high-quality, outsourced manufacturing services is expected to rise significantly.

A primary driver of this growth is the rapid advancement of personalized medicine and the increasing need for advanced diagnostic tests. As healthcare becomes more focused on tailored treatments, the use of immunoassay tests in identifying disease biomarkers has become more critical. The growing prevalence of chronic diseases and the demand for faster, more accurate diagnostic methods are fueling the need for robust immunoassay solutions. Immunoassay CDMOs play a crucial role in supporting the development and production of these diagnostics, ensuring that they meet regulatory standards while maintaining cost-effectiveness.

The rise in outsourcing by biotechnology and pharmaceutical companies is another key factor contributing to the growth of immunoassay CDMO services. By outsourcing the development and manufacturing of immunoassays, companies can focus on their core competencies while relying on specialized CDMOs to provide expert knowledge, high-quality production facilities, and compliance with stringent regulatory standards. As the demand for advanced diagnostic solutions continues to rise, the immunoassay CDMO industry in the USA is expected to see continued growth, driven by advancements in healthcare, diagnostics, and outsourcing trends.

What is the Segment-Wise Analysis of Demand for Immunoassay CDMO in USA?

Demand for immunoassay CDMO (Contract Development and Manufacturing Organization) services in the USA is segmented by services, end-users, and company size. By services, demand is divided into manufacturing and production, assay development and optimization, formulation and stability testing, analytical services, and others. The demand is also segmented by end-user, including diagnostic companies, biotech companies, and pharmaceutical companies. In terms of company size, demand is divided into small companies, mid-size companies, and large companies. Regionally, demand is divided into West USA, South USA, Northeast USA, and Midwest USA.

Why Does Manufacturing and Production Lead the Services Demand for Immunoassay CDMO?

Manufacturing and production account for 53% of the demand for immunoassay CDMO services in the USA. These services are critical for diagnostic companies, biotech firms, and pharmaceutical companies that require large-scale, high-quality production of immunoassay tests. The growing demand for diagnostic tests, including rapid antigen and PCR tests, has led to an increase in the need for reliable, efficient manufacturing and production services. Immunoassay CDMOs help in the mass production of these diagnostic products while maintaining stringent quality control, ensuring that they meet regulatory requirements. As the healthcare industry continues to expand and the demand for diagnostic testing grows, particularly in the wake of global health challenges, manufacturing and production services will remain essential to meeting the needs of the industry.

How Do Diagnostic Companies Lead the End-Use Demand for Immunoassay CDMO?

Diagnostic companies account for 48.2% of the demand for immunoassay CDMO services in the USA. These companies rely on CDMOs to provide the expertise and infrastructure needed to develop and manufacture diagnostic tests, including immunoassays, that are crucial for disease detection, monitoring, and treatment. With the increasing demand for diagnostic testing, especially in areas such as infectious diseases, cancer, and chronic conditions, diagnostic companies are seeking reliable partners to handle the production of these tests efficiently and at scale. CDMOs play a crucial role in offering specialized services like assay development, optimization, and manufacturing, enabling diagnostic companies to meet the growing industry needs. As healthcare becomes more focused on early diagnosis and personalized medicine, diagnostic companies will continue to drive the demand for immunoassay CDMO services in the USA.

What are the Key Trends, Drivers, and Restraints in Demand for Immunoassay CDMO in USA?

Demand for immunoassay CDMO services in the USA is growing as diagnostic companies, biotech firms, and pharma increasingly outsource immunoassay development and manufacturing rather than build in‑house capacity. Growth in the overall in‑vitro diagnostics (IVD) industry supports this demand, driven by rising rates of chronic and infectious diseases, increased testing volumes, and demand for timely, scalable diagnostics. Automated immunoassay platforms and high‑throughput testing are especially sought after, which strengthens CDMO demand. On the restraint side, the high cost of specialized equipment, regulatory compliance, and quality‑control requirements make it expensive to operate immunoassay CDMOs; competition among many service providers also pressures margins and can discourage new entrants or smaller players from scaling up.

Why is Demand for Immunoassay CDMO Growing in USA?

Immunoassay CDMO demand in the USA is rising because diagnostic firms and biotech companies need rapid, reliable, and regulatory‑compliant solutions to develop immunoassays from early R&D through manufacturing and commercialization. Outsourcing allows these firms to access specialized expertise and infrastructure without the capital burden, enabling faster time‑to‑industry for diagnostic kits. As diagnostics become more central to disease detection, monitoring, and personalized medicine (e.g., biomarkers, therapeutic monitoring, infectious‑disease screening), the need for high‑quality production capacity increases. In addition, growing demand for routine lab testing, hospital diagnostics, and point‑of‑care immunoassays fuel the uptake of CDMO services to meet volume and quality demands efficiently.

How are Technological and Industry Trends Driving Growth of Immunoassay CDMO in USA?

Technological and industry trends are significantly fueling immunoassay CDMO demand in the USA. Advances in assay automation, high‑throughput instrumentation, and improved reagent and kit‑manufacturing technologies make outsourced immunoassay production attractive and cost‑effective. Many CDMOs now offer full‑service packages from assay design and validation to large‑scale manufacturing, quality control, and regulatory support which reduce burden on diagnostic or biotech firms. Increased collaboration between diagnostic developers and CDMOs helps accelerate innovation and expand the range of tests (e.g., for emerging diseases, personalized diagnostics). As assay complexity rises (multiplex testing, high-sensitivity diagnostics), reliance on specialized CDMOs for consistent, scalable production becomes more pronounced.

What are the Key Challenges Limiting Wider Adoption of Immunoassay CDMO in USA?

Despite strong demand, several factors limit the growth of immunoassay CDMO services in the USA. The high upfront investment in specialized equipment, clean‑room facilities, quality‑control systems, and regulatory compliance makes it costly to establish or expand a CDMO facility which may deter smaller providers or limit scaling by newer entrants. Regulatory and quality requirements for diagnostic assays are stringent, requiring rigorous validation, documentation, and consistent manufacturing standards, which adds complexity and cost. increasing competition among many CDMOs creates pressure on pricing and margins. Industry saturation or overcapacity especially for common diagnostic assays may lead to reduced utilization of CDMO capacity, limiting returns and discouraging new investments.

What is the Regional Demand Outlook for Immunoassay CDMO in USA?

Region	CAGR (%)
West USA	9.7%
South USA	8.7%
Northeast USA	7.8%
Midwest USA	6.8%

Demand for Immunoassay CDMO services in the USA is growing steadily across all regions. The West leads with a 9.7% CAGR, driven by its biotechnology and pharmaceutical industries. The South follows with an 8.7% CAGR, supported by the region’s expanding healthcare and life sciences sectors. The Northeast shows a 7.8% CAGR, fueled by its well-established pharmaceutical and biotechnology hubs. The Midwest experiences a 6.8% CAGR, with steady demand coming from its pharmaceutical and medical device sectors. As the demand for personalized medicine, advanced diagnostics, and medical research continues to rise, demand for Immunoassay CDMO services is expected to grow across all regions, providing crucial support for the development and manufacturing of innovative diagnostic solutions.

What is Driving Immunoassay CDMO Demand in the West USA?

The West USA is leading the demand for Immunoassay CDMO services, with a 9.7% CAGR. The region’s biotechnology and pharmaceutical industries, particularly in California, Washington, and Oregon, are the main drivers of this demand. These states have a strong concentration of biotech firms and healthcare providers that rely on CDMO services to develop and manufacture immunoassays for diagnostics and therapeutic applications. The West’s focus on innovative healthcare solutions and personalized medicine has spurred the adoption of immunoassay technologies, driving the need for outsourcing development and manufacturing. With the region's strong investments in medical research and clinical trials, the demand for immunoassay CDMO services is expected to remain robust. The region’s emphasis on advanced diagnostics and immunotherapy is further fueling the demand for CDMO services to meet the growing need for customized diagnostic solutions.

How is Immunoassay CDMO Demand Growing in the South USA?

The South USA is experiencing strong demand for Immunoassay CDMO services, with an 8.7% CAGR. This growth is driven by the region's expanding healthcare and life sciences industries, particularly in states like Texas, Florida, and Georgia, where there is a growing focus on medical research, drug development, and healthcare innovation. The demand for immunoassays in the South is being supported by the increasing prevalence of chronic diseases and the rising focus on diagnostics and personalized medicine. With healthcare and pharmaceutical companies in the South seeking to meet the growing demand for high-quality, cost-effective immunoassay solutions, the need for outsourced CDMO services is on the rise. As the region continues to invest in medical infrastructure and biotech innovation, demand for immunoassay CDMO services is expected to grow, providing critical support for the development of new diagnostic tools and treatments.

Why is Immunoassay CDMO Demand Growing in the Northeast USA?

The Northeast USA is seeing steady demand for Immunoassay CDMO services, with a 7.8% CAGR. This demand is largely driven by the region's well-established pharmaceutical and biotechnology industries, particularly in cities like Boston, New York, and Philadelphia. These hubs are home to major pharmaceutical companies, research institutions, and hospitals, all of which require high-quality immunoassay development and manufacturing services to support clinical trials, diagnostics, and drug development. The Northeast’s strong focus on precision medicine, diagnostics, and advanced therapeutic solutions is fueling the demand for immunoassay CDMO services. As the region continues to lead in healthcare innovation and biotechnology research, demand for immunoassay services, including outsourcing of development and manufacturing, is expected to grow. The region’s emphasis on cutting-edge diagnostics and personalized medicine will continue to support the expansion of CDMO services.

What is Driving Immunoassay CDMO Demand in the Midwest USA?

The Midwest USA is seeing moderate demand for Immunoassay CDMO services, with a 6.8% CAGR. The demand in this region is driven by its strong pharmaceutical, medical device, and healthcare sectors, particularly in cities like Chicago, Indianapolis, and Detroit. As the Midwest continues to see growth in medical research, clinical trials, and diagnostic development, the need for outsourced Immunoassay CDMO services is increasing. The region's focus on advancing healthcare solutions and improving patient outcomes through diagnostics and personalized medicine is also contributing to the growing demand for immunoassay technologies. As the Midwest's pharmaceutical and medical device industries modernize and expand, they increasingly rely on contract development and manufacturing services to meet the growing demand for high-quality immunoassays. The moderate growth rate in this region reflects steady progress in both diagnostic and therapeutic applications, with continued demand expected as healthcare innovation advances.

What is the Competitive Landscape of Immunoassay CDMO Demand in USA?

Demand for Immunoassay Contract Development and Manufacturing Organizations (CDMO) in the USA is increasing as the biotechnology and pharmaceutical sectors continue to advance in diagnostics and therapeutic development. Immunoassays play a vital role in medical diagnostics, particularly in detecting diseases and monitoring patient conditions. As the demand for rapid and accurate testing increases, so does the need for CDMOs specializing in the development and manufacturing of immunoassay kits and reagents. The USA industry is seeing growth driven by the rising demand for personalized medicine, point-of-care testing, and improved diagnostic capabilities.

Key players in the Immunoassay CDMO industry in the USA include Firalis Molecular Precision, ProBio, Sanner GmbH, Biopharma Group, and GTP Bioways©. Firalis Molecular Precision leads the industry with a significant share of 15.8%, providing innovative services in the development and manufacturing of immunoassays for various therapeutic and diagnostic applications. ProBio offers a range of solutions for immunoassay production, focusing on high-quality, scalable manufacturing processes. Sanner GmbH specializes in packaging solutions and components for immunoassays, while Biopharma Group provides integrated services for the production of immunoassay reagents and diagnostics. GTP Bioways© provides custom manufacturing services for immunoassay kits, targeting both diagnostic and research sectors.

The competitive dynamics of the Immunoassay CDMO industry are driven by the increasing demand for more precise and rapid diagnostic tools, as well as the need for customized solutions. Companies compete by offering flexible, cost-effective, and high-quality development and manufacturing services. The ability to scale production, ensure regulatory compliance, and meet the specific needs of pharmaceutical and biotech companies is crucial. Advancements in immunoassay technologies, such as multiplex assays and point-of-care testing, are pushing companies to innovate and provide specialized solutions that cater to a broad range of medical and research applications.

Key Players in USA Immunoassay CDMO Demand

• Firalis Molecular Precision
• ProBio
• Sanner GmbH
• Biopharma Group
• GTP Bioways©

Scope of the Report

Metric	Value
Quantitative Units	USD 4.56 billion to USD 10.30 billion, at a CAGR of 8.5%
Market Definition	Based on FMI's report, the Immunoassay CDMO in USA market covers contract development and manufacturing services for immunoassay-based diagnostic products, including ELISA kits, lateral flow assays, chemiluminescence immunoassays, and related reagent systems outsourced by diagnostic, biotech, and pharmaceutical companies operating within the United States.
Segmentation	Services: Manufacturing and Production, Assay Development and Optimization, Formulation and Stability Testing, Analytical Services, Others; End User: Diagnostic Companies, Biotech Companies, Pharmaceutical Companies; Company Size: Small companies, Mid-size companies, Large companies
Regions Covered	West USA, South USA, Northeast USA, Midwest USA
Key Companies Profiled	Firalis Molecular Precision, ProBio, Sanner GmbH, Biopharma Group, GTP Bioways
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up methodology combining installed base metrics with regulatory compliance adoption curves and primary research validation.

USA Immunoassay CDMO Demand by Key Segments

Services

• Manufacturing and Production
• Assay Development and Optimization
• Formulation and Stability Testing
• Analytical Services
• Others

End User

• Diagnostic Companies
• Biotech Companies
• Pharmaceutical Companies

Company Size

• Small companies
• Mid-size companies
• Large companies

Region

• West USA
• South USA
• Northeast USA
• Midwest USA

Bibliography

• 1. USA Food and Drug Administration. (2025). Current Good Manufacturing Practice (cGMP) Regulations: 21 CFR Parts 210 and 211. FDA.
• 2. Centers for Medicare & Medicaid Services. (2025). Clinical Laboratory Improvement Amendments (CLIA) Program Statistics. CMS.
• 3. World Health Organization. (2024). WHO Expert Committee on Biological Standardization: Technical Report Series. WHO.
• 4. International Council for Harmonisation. (2024). ICH Q5E: Comparability of Biotechnological/Biological Products. ICH.
• 5. Organisation for Economic Co-operation and Development. (2025). Health at a Glance: Pharmaceutical Sector Indicators. OECD Publishing.
• 6. National Institutes of Health. (2025). NIH Funding for Diagnostic Assay Development: Annual Report. NIH.

This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with primary research documentation.